NY man's kidney transplant gave him woman's cancer

May 27, 2010 By JENNIFER PELTZ , Associated Press Writer

(AP) -- The scenario was unique, as far as doctors could tell: A man had gotten a transplanted kidney from a woman who had uterine cancer and didn't know it.

Vincent Liew decided to keep the kidney after his transplant surgeon concluded there was only a slim chance he could be sickened by the feminine cancer - advice that gambled with Liew's life and lost, a lawyer for his widow told jurors Thursday in what experts say may be the only known case of uterine cancer being transmitted by transplant.

Jurors began deliberating the case against NYU Langone Medical Center Thursday afternoon and were to return on Friday.

Langone should be held responsible "for taking a huge risk with Vincent Liew's life" by not urging him to have the kidney removed at once, Daniel Buttafuoco said during closing arguments in the medical-malpractice case, which is refreshing longstanding questions about risks and rewards.

NYU Langone Medical Center says it advised Liew of the risk, honored his choice and aggressively monitored the kidney for signs of cancer. Though tests found nothing, Liew suffered back pain and ultimately had the kidney removed about six months after the 2002 transplant. He died about three weeks later of cancer that came from his donor, his said, without specifying the type of cancer. He was 37.

"This should not have happened, but it's not NYU Medical Center's fault. It's not ( Dr. Thomas) Diflo's fault. It's not Mr. Liew's fault," the hospital's lawyer, Robert Elliott, said in his summation. "The best care that could have been provided was."

Liew's widow, Kimberly, is seeking more than $3 million in damages in her lawsuit against the hospital.

Liew, originally from Singapore, worked in the Hong Kong Economic and Trade Office in New York. A diabetic since his teens who was on three-times-a-week , he had been awaiting a kidney for about five years when he got the transplant Feb. 25, 2002.

The donor, Sandy Cabrera, 50, had died of a stroke about a day earlier in Newburgh, N.Y. "No one knew she had cancer," her boyfriend, Michael Daniels, said in a telephone interview.

An autopsy in the days after her death found that she had uterine cancer that had begun to spread to her lungs.

The news didn't reach Diflo until mid-April 2002, according to trial testimony. The hospital that treated Cabrera, St. Luke's Cornwall, declined to comment.

The organization that arranged the transplant, the New York Organ Donor Network, referred inquiries on Thursday to a national transplant group, the United Network for Organ Sharing, that declined comment.

With no medical literature available on uterine cancer being transmitted by transplant, Diflo testified that he told Liew the safest plan was removing the , but that the odds of Liew developing the cancer were slight.

In dueling testimony from cancer specialists, the two sides have disputed whether it was indeed uterine cancer that killed Liew, though both acknowledge the malignancy derived from the transplant and caused his death.

A cancer expert who reviewed Liew's records and testified for NYU, Dr. Jeffrey Schneider of Winthrop University Hospital in Mineola, said Thursday he believed Liew suffered from a type of immune-system cancer that sometimes afflicts transplant patients.

The federal Centers for Disease Control and Prevention estimate that 1 percent of U.S. organ transplants are suspected of transmitting illnesses, though data are sparse.

Some 23 transplant recipients in 2007 - out of about 28,000 recipients nationwide that year - were judged to have at least possibly contracted cancers, HIV, tuberculosis and other diseases from their donors, according to a 2009 article in the American Journal of Transplantation. Twelve of the recipients died, according to the article, which examined reports made to the national Organ Procurement and Transplantation Network.

Potential donors are screened for various diseases, and those with active cancers generally are eliminated from consideration. But some cancers and other diseases can't always be detected in the short time frame transplants require, usually within a day, said Dr. Jeffrey D. Punch, the University of Michigan Health Systems' transplant chief.


Related Stories

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

1 / 5 (3) May 27, 2010
I'm supposing cancer is transmittable in transplant patients because the anti-rejection drugs protect the cancer from an immune response.

Therefore, couldn't they have reduced (or eliminated) the threat simpy by modulating the anti-rejection drugs a bit to allow his own body to respond to the foreign cells, cure the cancer, and retain a mostly still funtioning kidney?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.